SAREPTA THERAPEUTICS, INC. Operating Expenses
SAREPTA THERAPEUTICS, INC. (SRPT) reported Operating Expenses of $56.53 million for the 3-month period ending 2016-09-30, per its 10-Q filed 2016-11-07.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2016-11-07
- SAREPTA THERAPEUTICS, INC. operating expenses for the quarter ending 2016-09-30 was $56.53M, a 9.22% increase year-over-year.
- SAREPTA THERAPEUTICS, INC. operating expenses for the quarter ending 2016-06-30 was $62.10M, a 47.48% increase year-over-year.
- SAREPTA THERAPEUTICS, INC. operating expenses for the quarter ending 2016-03-31 was $59.70M, a 3.49% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. operating expenses for the quarter ending 2015-12-31 was $65.70M, a 46.83% increase year-over-year.
- SAREPTA THERAPEUTICS, INC. operating expenses for fiscal 2015 was $221.44M, a 54.26% increase from fiscal 2014.
- SAREPTA THERAPEUTICS, INC. operating expenses for fiscal 2014 was $143.55M, a 37.36% increase from fiscal 2013.
- SAREPTA THERAPEUTICS, INC. operating expenses for fiscal 2013 was $104.50M, a 55.90% increase from fiscal 2012.
- SAREPTA THERAPEUTICS, INC. operating expenses for fiscal 2012 was $67.03M.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2016-09-30 | $56.53M 10-Q · filed 2016-11-07 | $118.63M derived: sum of 2 quarters · filed 2016-11-07 | $178.34M 10-Q · filed 2016-11-07 | $244.04M derived: sum of 4 quarters · filed 2016-11-07 |
| 2016-06-30 | $62.10M 10-Q · filed 2016-08-09 | $121.80M 10-Q · filed 2016-08-09 | $187.51M derived: sum of 3 quarters · filed 2016-08-09 | $239.27M derived: sum of 4 quarters · filed 2016-11-07 |
| 2016-03-31 | $59.70M 10-Q · filed 2016-05-05 | $125.41M derived: sum of 2 quarters · filed 2016-05-05 | $177.17M derived: sum of 3 quarters · filed 2016-11-07 | $219.28M derived: sum of 4 quarters · filed 2016-11-07 |
| 2015-12-31 | $65.70M 10-K · filed 2016-02-25 | $117.47M derived: sum of 2 quarters · filed 2016-11-07 | $159.57M derived: sum of 3 quarters · filed 2016-11-07 | $221.44M 10-K · filed 2016-02-25 |
| 2015-09-30 | $51.76M 10-Q · filed 2016-11-07 | $93.87M derived: sum of 2 quarters · filed 2016-11-07 | $155.73M 10-Q · filed 2016-11-07 | $200.48M derived: sum of 4 quarters · filed 2016-11-07 |
| 2015-06-30 | $42.11M 10-Q · filed 2016-08-09 | $103.97M 10-Q · filed 2016-08-09 | $148.72M derived: sum of 3 quarters · filed 2016-08-09 | $183.45M derived: sum of 4 quarters · filed 2016-08-09 |
| 2015-03-31 | $61.86M 10-Q · filed 2016-05-05 | $106.61M derived: sum of 2 quarters · filed 2016-05-05 | $141.34M derived: sum of 3 quarters · filed 2016-05-05 | $174.20M derived: sum of 4 quarters · filed 2016-05-05 |
| 2014-12-31 | $44.75M 10-K · filed 2016-02-25 | $79.48M derived: sum of 2 quarters · filed 2016-02-25 | $112.34M derived: sum of 3 quarters · filed 2016-02-25 | $143.55M 10-K · filed 2016-02-25 |
| 2014-09-30 | $34.73M 10-K · filed 2016-02-25 | $67.59M derived: sum of 2 quarters · filed 2016-02-25 | $98.80M 10-Q · filed 2015-11-05 | $134.27M derived: sum of 4 quarters · filed 2016-02-25 |
| 2014-06-30 | $32.85M 10-K · filed 2016-02-25 | $64.06M 10-Q · filed 2015-08-06 | $99.54M derived: sum of 3 quarters · filed 2016-02-25 | $128.64M derived: sum of 4 quarters · filed 2016-02-25 |
| 2014-03-31 | $31.21M 10-K · filed 2016-02-25 | $66.68M derived: sum of 2 quarters · filed 2016-02-25 | $95.78M derived: sum of 3 quarters · filed 2016-02-25 | $115.82M derived: sum of 4 quarters · filed 2016-02-25 |
| 2013-12-31 | $35.48M 10-K · filed 2015-02-26 | $64.58M derived: sum of 2 quarters · filed 2015-02-26 | $84.61M derived: sum of 3 quarters · filed 2015-02-26 | $104.50M 10-K · filed 2016-02-25 |
| 2013-09-30 | $29.10M 10-K · filed 2015-02-26 | $49.14M derived: sum of 2 quarters · filed 2015-02-26 | $69.03M derived: sum of 3 quarters · filed 2015-02-26 | |
| 2013-06-30 | $20.04M 10-K · filed 2015-02-26 | $39.93M derived: sum of 2 quarters · filed 2015-02-26 | ||
| 2013-03-31 | $19.89M 10-K · filed 2015-02-26 | |||
| 2012-12-31 | $67.03M 10-K · filed 2015-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |